检索结果 - Kenneth W. Mahaffey
- Showing 1 - 20 results of 215
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus 由 Gemma A. Figtree, Karin Rådholm, Terrance D. Barrett, Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, David R. Matthews, Wayne Shaw, Bruce Neal
出版 2019Carta -
15
-
16
-
17
-
18
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure 由 Sok Cin Tye, Niels Jongs, Steven G. Coca, Johan Sundström, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Priya Vart, Hiddo J.L. Heerspink
出版 2022Artigo -
19
Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes 由 Daniel Lindholm, Stefan James, Katja Gabrysch, Robert F. Storey, Anders Himmelmänn, Christopher P. Cannon, Kenneth W. Mahaffey, Philippe Gabríel Steg, Claes Held, Agneta Siegbahn, Lars Wallentin
出版 2018Artigo -
20
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial 由 Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Peter Stein, Mehul Desai, Wayne Shaw, Joel Jiang, Frank Vercruysse, Gary Meininger, David R. Matthews
出版 2013Artigo
相关主题
Medicine
Internal medicine
Cardiology
Confidence interval
Myocardial infarction
Atrial fibrillation
Hazard ratio
Endocrinology
Diabetes mellitus
Engineering
Mechanical engineering
Stroke (engine)
Type 2 diabetes
Canagliflozin
Randomized controlled trial
Warfarin
Alternative medicine
Kidney disease
Pathology
Placebo
Acute coronary syndrome
Rivaroxaban
Intensive care medicine
Heart failure
Renal function
Clinical endpoint
Clopidogrel
Percutaneous coronary intervention
Surgery
Ticagrelor